INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 421s ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
SEC FORM 4/Open-market purchaseVerified data

Ciongoli Gregory Austin bought RGNX

Director · REGENXBIO Inc. · Common Stock

Side
BUY
Value
$500K
Shares
53.4K
Price
$9.36
Executed
Aug 27, 2026
Disclosed
Aug 27, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Aug 27 executedAug 27, 2026 disclosed

RGNX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
43/ 100 · ELEVATED
Methodology →
  • Transaction type+20 / 20

    Open-market purchase

  • Relative size+19 / 25

    $500K reported value · 82.6% of prior position

  • Filing timing0 / 15

    Disclosed 0 business days after execution (deadline: 2)

  • Historical behavior+4 / 15

    1 prior trade recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · RGNX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    17
    MC
    Malzahn CraigChief Technology Officer
    RGNXREGENXBIO Inc.
    Grant or award
    		A—
    27.8K sh
    		Nov 1, 2026Nov 3, 2026
    traded Nov 1, 2026
    		+2dSEC FORM 4

    Evidence

    9
    MC
    Malzahn CraigChief Technology Officer
    RGNXREGENXBIO Inc.
    Tax withholding
    		F$2,181
    234 sh
    		Sep 1, 2026Sep 3, 2026
    traded Sep 1, 2026
    		+2dSEC FORM 4

    Evidence

    9
    CA
    Ciongoli Gregory AustinDirector
    RGNXREGENXBIO Inc.
    Grant or award
    		A—
    69.6K sh
    		Aug 25, 2026Aug 27, 2026
    traded Aug 25, 2026
    		+2dSEC FORM 4

    Evidence

    9
    CA
    Ciongoli Gregory AustinDirector
    RGNXREGENXBIO Inc.
    Grant or award
    		A—
    15.4K sh
    		Aug 25, 2026Aug 27, 2026
    traded Aug 25, 2026
    		+2dSEC FORM 4

    Evidence

    47
    CA
    Ciongoli Gregory AustinDirector
    RGNXREGENXBIO Inc.
    Open-market purchase
    		BUY$450K
    49.2K sh
    		Aug 26, 2026Aug 27, 2026
    traded Aug 26, 2026
    		+1dSEC FORM 4

    Evidence

    21
    MC
    Malzahn CraigChief Technology Officer
    RGNXREGENXBIO Inc.
    Grant or award
    		A—
    65.8K sh
    		Jan 6, 2026Jan 8, 2026
    traded Jan 6, 2026
    		+2dSEC FORM 4

    Evidence

    9
    MC
    Malzahn CraigChief Technology Officer
    RGNXREGENXBIO Inc.
    Grant or award
    		A—
    35.4K sh
    		Jan 6, 2026Jan 8, 2026
    traded Jan 6, 2026
    		+2dSEC FORM 4

    Evidence

    21
    CM
    Chan MitchellChief Financial Officer
    RGNXREGENXBIO Inc.
    Grant or award
    		A—
    73.7K sh
    		Jan 6, 2026Jan 8, 2026
    traded Jan 6, 2026
    		+2dSEC FORM 4

    Evidence

    9
    CM
    Chan MitchellChief Financial Officer
    RGNXREGENXBIO Inc.
    Grant or award
    		A—
    39.6K sh
    		Jan 6, 2026Jan 8, 2026
    traded Jan 6, 2026
    		+2dSEC FORM 4

    Evidence

    13
    MC
    Malzahn CraigChief Technology Officer
    RGNXREGENXBIO Inc.
    Tax withholding
    		F$18K
    1,238 sh
    		Jan 2, 2026Jan 6, 2026
    traded Jan 2, 2026
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002023732-26-000008
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Aug 27, 2026
    Published
    Aug 27, 2026
    Ingested by INSIDER
    Nov 5, 02:20 UTC
    Last re-read
    Nov 5, 02:20 UTC

    Extracted facts

    Filer
    Ciongoli Gregory Austin
    Role
    Director
    Transaction
    Open-market purchaseAs filed: “P”
    Asset
    REGENXBIO Inc.
    Ticker
    RGNX
    Shares
    53.4K
    Price per share
    $9.36
    Value
    $499,676
    Execution date (reported)
    Aug 27, 2026
    Owned after transaction
    118.0K shares
    Days from execution to publication
    0

    Calculation

    Value = shares × reported price per share

    • Shares: 53.4K
    • Price: $9.356

    = $499,676

    What this establishes

    Ciongoli Gregory Austin filed this Form 4 reporting a open-market purchase of RGNX on Aug 27, 2026. It became public on Aug 27, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Ciongoli Gregory Austincik:0002023732
    Issuer
    REGENXBIO Inc.cik:0001590877

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.